2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology

Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading

SCP 25

December 12 to December 15, 2016 WIPO’s Page on the Meeting SCP 25: Opening statement of Knowledge Ecology International SCP25: Statement of Asia Pacific Group on Patents and Health SCP25: South Africa’s Experience Related to the Topic of Access to… Continue Reading

SCP 27

December 11 to December 15, 2017 WIPO’s Page for the Meeting SCP27: WIPO patent committee agrees to future work on patent oppositions, exceptions and limitations, and patents and health SCP27: South Africa urges WIPO to invite UNHLP Co-Chairs to present… Continue Reading

Trade Policy Reviews

KEI page on the World Trade Organization’s (WTO) Trade Policy Reviews All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually… Continue Reading

18 members of the House of Representatives call for compulsory license on patents for HCV treatments

Representative Ro Khanna (D-CA-17) was joined by 17 other members of Congress in calling upon Department of Health and Human Services Secretary Alex Azar to issue a compulsory license on patents for medications to treat hepatitis C, by exercising 28… Continue Reading

October 2017: Dueling narratives on compulsory licensing emerge from the WTO TRIPS Council

The October 2017 meeting of the WTO TRIPS Council witnessed heated discussions on compulsory licensing within the context of IP and the Public Interest. As reported earlier by Knowledge Ecology International, on 31 May 2017, Brazil, China, Fiji, India, and… Continue Reading

NIH Declines Request for the Budget for Clinical Trials Involving CAR T technology to be licensed to Kite/Gilead

On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading

Colombia

Blogs about compulsory licensing in Colombia are here.